Short-Term Efficacy and Safety of Basal-Bolus Insulin Regimens in Renal Transplant Recipients With Pre-existing Type 2 Diabetes Mellitus in Early Post-transplant Outpatient Settings

Introduction Glycemic control is important for allograft and patient survival in renal transplant recipients. We evaluated short-term treatment outcomes of basal-bolus insulin regimens during outpatient diabetes management in renal transplant recipients with pre-existing diabetes. Materials and methods In this 24-week retrospective observational study, 112 adults with pre-existing type 2 diabetes mellitus (T2DM) who underwent renal transplantation were evaluated for changes in HbA1c, fasting plasma glucose (FPG), postprandial plasma glucose (PPG), serum creatinine, estimated glomerular filtration rate (eGFR), body weight, and hypoglycemic episodes during 24 weeks of outpatient management with basal-bolus insulin regimens. Results Basal-bolus insulin therapy was associated with significant reductions in mean HbA1c (8.9% to 7.2%; p < 0.001), FPG (237.9 to 122.3 mg/dL; p < 0.001), and PPG (342.2 to 173.0 mg/dL; p < 0.001). Overall, 45.5% of patients achieved HbA1c ≤7%, while 46.4% achieved HbA1c >7% and <8%. Body weight increased modestly (mean weight gain of 1.24 kg), with numerically greater weight gain in the glargine group, although the difference was not statistically significant in the primary analysis (p = 0.061). No statistically significant differences in glycemic or renal outcomes were observed between the degludec and glargine groups or between the regular human insulin and insulin aspart groups. Nocturnal hypoglycemia occurred in four of 60 (6.7%) patients receiving degludec and seven of 52 (13.5%) patients receiving glargine; however, the difference was not statistically significant (p = 0.341). Conclusions Glycemic control improved over 24 weeks among renal transplant recipients with pre-existing T2DM receiving basal-bolus insulin therapy, without deterioration in measured renal function parameters. No statistically significant differences in glycemic outcomes or the proportions of patients experiencing nocturnal hypoglycemia were observed between the degludec and glargine groups.

Authors

Publication Details

Journal
Cureus
Published
2026-11-18
DOI
https://doi.org/10.7759/cureus.119913
Primary Topic
Diabetes Management and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Short-Term Efficacy and Safety of Basal-Bolus Insulin Regimens in Renal Transplant Recipients With Pre-existing Type 2 Diabetes Mellitus in Early Post-transplant Outpatient Settings

Debmalya Sanyal, Sourav Das Choudhury
Cureus
Diabetes Management and Research
article

Short-Term Efficacy and Safety of Basal-Bolus Insulin Regimens in Renal Transplant Recipients With Pre-existing Type 2 Diabetes Mellitus in Early Post-transplant Outpatient Settings

Debmalya Sanyal, Sourav Das Choudhury
article en

Abstract

Introduction Glycemic control is important for allograft and patient survival in renal transplant recipients. We evaluated short-term treatment outcomes of basal-bolus insulin regimens during outpatient diabetes management in renal transplant recipients with pre-existing diabetes. Materials and methods In this 24-week retrospective observational study, 112 adults with pre-existing type 2 diabetes mellitus (T2DM) who underwent renal transplantation were evaluated for changes in HbA1c, fasting plasma glucose (FPG), postprandial plasma glucose (PPG), serum creatinine, estimated glomerular filtration rate (eGFR), body weight, and hypoglycemic episodes during 24 weeks of outpatient management with basal-bolus insulin regimens. Results Basal-bolus insulin therapy was associated with significant reductions in mean HbA1c (8.9% to 7.2%; p < 0.001), FPG (237.9 to 122.3 mg/dL; p < 0.001), and PPG (342.2 to 173.0 mg/dL; p < 0.001). Overall, 45.5% of patients achieved HbA1c ≤7%, while 46.4% achieved HbA1c >7% and <8%. Body weight increased modestly (mean weight gain of 1.24 kg), with numerically greater weight gain in the glargine group, although the difference was not statistically significant in the primary analysis (p = 0.061). No statistically significant differences in glycemic or renal outcomes were observed between the degludec and glargine groups or between the regular human insulin and insulin aspart groups. Nocturnal hypoglycemia occurred in four of 60 (6.7%) patients receiving degludec and seven of 52 (13.5%) patients receiving glargine; however, the difference was not statistically significant (p = 0.341). Conclusions Glycemic control improved over 24 weeks among renal transplant recipients with pre-existing T2DM receiving basal-bolus insulin therapy, without deterioration in measured renal function parameters. No statistically significant differences in glycemic outcomes or the proportions of patients experiencing nocturnal hypoglycemia were observed between the degludec and glargine groups.

Cureus
Diabetes Management and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon